Webinar Date/Time: Tuesday, June 25th, 2024 at 11am EDT|8am PDT|4pm BST|5pm CEST
Related Posts
FDA Priority Review Granted to Augtyro for Solid Tumors Based on Phase I/II TRIDENT-1 Trial Data
Image credit: peterschreiber.media | stock.adobe.com. Bristol Myers Squibb’s supplemental New Drug Application (sNDA) for Augtyro (repotrectinib) has been granted Priority…
A Disruption in the Clinical Research Enterprise
In a recent video interview with Applied Clinical Trials, Michael Liu, medical student and researcher at Harvard Medical School, discussed…
Astegolimab Shows Mixed Results in COPD Trials, Meeting Endpoint in ALIENTO but Not in ARNASA
Image Credit: © peterschreiber.media – stock.adobe.com Key takeaways The ALIENTO Phase IIb study met its primary endpoint, demonstrating a 15.4%…